Figure 1
From: Nilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year
Study population SARA: Scale for the Assessment and Rating of Ataxia and ADSCA: autosomal dominant spinocerebellar ataxia.
Figure 1 | Scientific Reports
